{
  "docId": "019de073-8778-764b-accb-e5886cb9e840",
  "docSlug": "a27c0c380497fe380fc0ea99c606f1fe",
  "documentTitle": "Equillium | Results Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 32,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The chart shows concentration over time for different dosage groups (0.4 to 3.2 mg/kg) for Type A and Type B subjects.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8778-764b-accb-e5886cb9e840/25",
  "deckHref": "/decks/019de073-8778-764b-accb-e5886cb9e840",
  "deckJsonHref": "/decks/019de073-8778-764b-accb-e5886cb9e840.json",
  "deckAnchorHref": "/decks/019de073-8778-764b-accb-e5886cb9e840#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "chart",
      "text": "PK similar between Type A and B subjects",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbd58c0f-c1de-4bcb-aa52-199adc760c4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.12,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Based on interim data from 2 Sep 2022 – subject to change; Putterman et al., PO1623, ASN 2021\nAbbreviations: ADA: anti-drug antibody; PD: pharmacodynamic; PK: Pharmacokinetic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "004d5d77-3dca-4f53-8c6d-b08dedb5eea0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "PK profile at 1.6 mg/kg comparable between Type A and B patients\nReduction of cell surface CD6 (PD marker) is consistent with the mechanism of action\nTo date, no subjects exhibited high titers of ADA, no changes to PK in ADA positive subjects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fde42f2-a0c5-42d2-8469-c4e27d0c471d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Assessment of PK/PD and Anti-Drug Antibodies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "356cdfc3-884c-4589-b509-2deeb8a89d9e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 10,
      "beatId": "74c9ceff-f718-432a-b48e-9f41e627272b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Itolizumab's potential solution is presented, with efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 31,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f935949f-a063-4f53-ae76-c20f25bdff22",
      "evidence": "The presentation implies the cost of inaction through the unmet medical need and limitations of current treatments.",
      "position": 0,
      "objective": "What is the cost of not treating Lupus Nephritis effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5a9857ab-edc2-421f-aac9-92c4e50656db",
      "evidence": "The presentation discusses itolizumab's mechanism of action and efficacy in treating Lupus Nephritis.",
      "position": 1,
      "objective": "What are the jobs to be done in treating Lupus Nephritis?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}